Atara Biotherapeutics, a company that develops treatments for patients with cancer, autoimmune and viral diseases, announced Oct. 25 that its general counsel plans on leaving her role, but will remain with the company as a consultant until early April.

Mina Kim, senior vice president, corporate strategy and general counsel, was not available for comment Monday. In a news release announcing her departure, the company said a replacement has not yet been named, and the company,based in South San Francisco, will begin the process of looking for a new general counsel.